<DOC>
	<DOCNO>NCT02044861</DOCNO>
	<brief_summary>ACT-PFK-158 novel anti-cancer agent inhibits glucose uptake cancer cell . The primary objective study determine maximum tolerate dose ( MTD ) describe dose limit toxicity . The secondary objective study determine safety profile drug , determine pharmacokinetic profile , identify anti-tumor activity , determine pharmacodynamic profile ACT-PFK-158 .</brief_summary>
	<brief_title>Phase 1 Safety Study ACT-PFK-158 , 2HCl Patients With Advanced Solid Malignancies</brief_title>
	<detailed_description />
	<criteria>1 . Histological cytological evidence solid malignancy . 2 . Patients must : . Have advance solid tumor refractory establish therapy know provide clinical benefit malignancy question , OR b . Be intolerant establish therapy know provide clinical benefit malignancy question 3 . Patients enrolled doseexpansion part trial must least one lesion may qualify target lesion base RECIST 1.1 criterion . 4 . Patient ambulatory ECOG performance status 0 , 1 2 estimate life expectancy &gt; 3 month . 5 . Patient 18 year old . 6 . Patients legal representative must ability read , understand provide write informed consent initiation study related procedure . 7 . Patients must adequate bone marrow reserve evidence : a. WBC &gt; 3,000/µL b . Absolute neutrophil count ( ANC ) ≥ 1,500/µL c. Platelet count ≥ 100,000/µL d. Hemoglobin ≥ 9 gm/dL . 8 . Patients must adequate renal function evidence serum creatinine ≤ 1.5 X ULN reference laboratory OR calculate creatinine clearance ≥ 60 mL/min CockroftGault equation . 9 . Patients must adequate hepatic function evidence AST ALT value ≤ 3 X ULN ( ≤ 5 X ULN liver know involve metastatic disease ) serum total bilirubin value ≤ 1.5 X ULN reference laboratory . 10 . Patients must INR PTT value ≤ 1.5X ULN reference laboratory . 11 . Patients must recover effect prior chemotherapy , radiotherapy surgery ( i.e. , toxicity bad Grade 1 ) ; patient monoclonal antibody therapy , least one halflife 4 week ( whichever short ) elapse prior first schedule day dose PFK158 . 12 . Patients prior investigational agent must wait least 5 halflives enrollment trial , 4 week halflife investigational agent know . 13 . Female patient childbearing potential must negative pregnancy test within 7 day start treatment . 14 . Women childbearing potential men female sexual partner childbearing potential must agree use effective method contraception ( e.g. , oral contraceptive , doublebarrier method condom diaphragm , intrauterine device ) study 90 day follow last dose study medication abstain sexual intercourse time ; woman childbearing potential one undergone bilateral oophorectomy postmenopausal , define menstrual period 12 consecutive month . 1 . Patients active infection fever ≥ 38.5°C within 3 day first schedule day dose . 2 . Patients primary CNS tumor well patient CNS metastasis exclude . 3 . Patients know hypersensitivity component PFK158 . 4 . Patients receive investigational therapy treat investigational therapy investigational device within 5 halflives investigational therapy 4 week first schedule day dose PFK158 halflive investigational agent know . 5 . Uncontrolled hypertension define SBP &gt; 160 mm/Hg DBP &gt; 100 mm/Hg despite medical therapy . 6 . Subjects diabetes . 7 . Patients require pharmacologic dos corticosteroid ; replacement , topical , ophthalmologic inhalational steroid permit . 8 . Patients require coumadin administration . 9 . Patients mean QTcF value &gt; 470 msec ( female ) &gt; 450 msec ( male ) follow 3 ECGs conduct 5 minute apart ; patient know congenital prolonged QT syndrome ; patient medication know cause prolong QT interval ECG . 10 . Patients clinically significant cardiovascular comorbidities include : congestive heart failure ( New York Heart Association class IIIIV heart disease ) , unstable angina pectoris , cardiac arrhythmia require medication pacemaker ; myocardial infarction within past six month ; stroke within past 6 month ; hypertension require 2 medication blood pressure control . 11 . Patients concurrent uncontrolled illness , include mental illness substance abuse , may interfere ability patient cooperate participate trial ; example condition would include COPD diabetes mellitus require 2 hospitalization last year ; severe peripheral vascular disease ; poorly control autoimmune condition ; recent serious trauma . 12 . Grade 2 high peripheral neuropathy . 13 . Patients currently know positive , HIV , hepatitis B C. 14 . Patients pregnant lactate . 15 . Concurrent recent ( within 1 month ) use thrombolytic agent , fulldose anticoagulant ( except maintain patency preexisting , permanent indwell IV catheter ) . Of note , therapy lowmolecular weight heparin acceptable long INR &lt; 2.0 . 16 . Significant traumatic injury within past 4 week . 17 . Patients inpatient .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
</DOC>